OCGN
Ocugen, Inc.
1.12
+
0.00
0.00%
7 x 1.10
7 x 1.13
bid
ask
7 @ 04:00 PM
1.12+0.00 (0.00%)
Bearish
169
Bullish
423
sentiment
1.10
day range
1.18
0.34
52 week range
2.10
News
...
Ocugen Inc. stock falls Tuesday, underperforms market | news.google.com • |
Ocugen Inc. stock falls Tuesday, underperforms market | news.google.com • |
Ocugen Inc. stock falls Tuesday, underperforms market | news.google.com • |
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 | seekingalpha.com • |
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 | news.google.com • |
NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation | news.google.com • |
Profile
...
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | -0.06 | -0.04 | 0.02 | 33.33% |
2024-05-14 | 2024-03 | -0.06 | -0.05 | 0.01 | 16.67% |
2024-04-16 | 2023-12 | 0 | -0.04 | N/A | N/A |
2023-11-09 | 2023-09 | -0.08 | -0.06 | 0.02 | 25.00% |
2023-08-21 | 2023-06 | -0.08 | -0.1 | -0.02 | -25.00% |
2023-05-05 | 2023-03 | -0.11 | -0.07 | 0.04 | 36.36% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-07 | Chardan Capital | Upgrade | Buy | |
2023-04-16 | HC Wainwright & Co. | Upgrade | Buy | |
2023-04-13 | Chardan Capital | Upgrade | Buy | |
2023-02-28 | Chardan Capital | Upgrade | Neutral | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-08-10 | CASTILLO KIRSTEN M | Director | 50.00K | Sale |
2023-01-02 | CRESPO JESSICA | Officer | 163.39K | Stock Award(Grant) |
2021-05-24 | FERNANDES PRABHAVATHI | Director | 0.00 | Sale |
2021-11-01 | KOMPELLA UDAY B. | Director | 0.00 | Sale |
2022-10-05 | KUMAR RAMESH | Director | 0.00 | Sale |
2023-02-15 | MUSUNURI SHANKAR PH.D | Chief Executive Officer | 3.34M | Sale |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 11.81M | 6.41M | 4.60% |
2023-06-29 | Luminus Management, LLC | 4.08M | 2.22M | 1.59% |
2023-06-29 | GMT Capital Corp | 3.92M | 2.13M | 1.53% |
2023-06-29 | Blackrock Inc. | 3.91M | 2.12M | 1.52% |
2023-06-29 | JP Morgan Chase & Company | 3.04M | 1.65M | 1.19% |
2023-06-29 | Millennium Management Llc | 3.02M | 1.64M | 1.18% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 7.60M | 4.13M | 2.96% |
2023-06-29 | Vanguard Extended Market Index Fund | 3.06M | 1.66M | 1.19% |
2023-05-30 | Fidelity Extended Market Index Fund | 1.07M | 490.29K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 921.56K | 423.92K | 0.36% |
2023-05-30 | Vanguard Health Care Index Fund | 738.21K | 339.58K | 0.29% |
2023-05-30 | Vanguard Russell 2000 Index Fund | 597.25K | 274.74K | 0.23% |
Split
...
Split | Date |
---|---|
1 : 60 | 2019-09-30 |
This topic has been deleted. Only users with topic management privileges can see it.
-
$OCGN If its Novartis, this thing will explode… forget about to the Moon! This thing will leave the Universe
-
$OCGN Green in a blink of an eye 🤩🤩
-
$OCGN we wil finish green again… same same
-
$OCGN and back up we go 🤩🤩
-
$OCGN like always… shorts attack the stock but by the end of the day we are up again
-
$OCGN expecting alot today
-
$OCGN Tomorrow even $ 2.00 is possible
-
$OCGN do you believe me now?! 🤩
-
$OCGN Let‘s see today ️
-
$OCGN IT WANTS TO BREAK FREE
-
$OCGN Again run befor closing?
-
-
-
$OCGN will get back up again in my opinion. They got an amazing pipeline… so we wait and see
-
$OCGN I‘m so optimistic!!!
-
Ocugen Inc. stock falls Tuesday, underperforms market
news.google.com • -
Ocugen Inc. stock falls Tuesday, underperforms market
news.google.com • -
Ocugen Inc. stock falls Tuesday, underperforms market
news.google.com • -
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
seekingalpha.com • -
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
news.google.com • -
Ocugen Inc. stock rises Friday, outperforms market
news.google.com • -
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
globenewswire.com • -
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
globenewswire.com • -
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
globenewswire.com • -
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
globenewswire.com • -
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
investorplace.com • -
Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles
seekingalpha.com •